{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:03:44Z","timestamp":1791392624855,"version":"4.3.3"},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.arr.2024.102651","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T06:01:16Z","timestamp":1736056876000},"page":"102651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Drug repositioning for Parkinson\u2019s disease: An emphasis on artificial intelligence approaches"],"prefix":"10.1016","volume":"104","author":[{"given":"Iman","family":"Karimi-Sani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Abolpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrzad","family":"Lotfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Atapour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Ali","family":"Takhshid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2024.102651_bib1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/jcc.540150503","article-title":"ICM\u2014A new method for protein modeling and design: applications to docking and structure prediction from the distorted native conformation","volume":"15","author":"Abagyan","year":"1994","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.arr.2024.102651_bib2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/JAD-2006-9309","article-title":"Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders","volume":"9","author":"Abdi","year":"2006","journal-title":"J. Alzheimer'S. Dis."},{"key":"10.1016\/j.arr.2024.102651_bib3","doi-asserted-by":"crossref","first-page":"8717","DOI":"10.1109\/TPAMI.2018.2889052","article-title":"Deep audio-visual speech recognition","volume":"44","author":"Afouras","year":"2018","journal-title":"IEEE Trans. Pattern Anal. Mach. Intell."},{"key":"10.1016\/j.arr.2024.102651_bib4","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1186\/s12909-023-04698-z","article-title":"Revolutionizing healthcare: the role of artificial intelligence in clinical practice","volume":"23","author":"Alowais","year":"2023","journal-title":"BMC Med. Educ."},{"key":"10.1016\/j.arr.2024.102651_bib5","doi-asserted-by":"crossref","first-page":"15731","DOI":"10.1074\/jbc.M117.791863","article-title":"The unintended mitochondrial uncoupling effects of the FDA-approved anti-helminth drug nitazoxanide mitigates experimental parkinsonism in mice","volume":"292","author":"Amireddy","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.arr.2024.102651_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2176\/nmc.ra.2018-0045","article-title":"Can the latest computerized technologies revolutionize conventional assessment tools and therapies for a neurological disease? the example of Parkinson\u2019s disease","volume":"59","author":"Asakawa","year":"2019","journal-title":"Neurol. Med. Chir."},{"key":"10.1016\/j.arr.2024.102651_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/WNF.0b013e318170576c","article-title":"Methylphenidate for the treatment of Parkinson disease and other neurological disorders","volume":"32","author":"Auriel","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.arr.2024.102651_bib8","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson's disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.arr.2024.102651_bib9","doi-asserted-by":"crossref","first-page":"D1276","DOI":"10.1093\/nar\/gkac1085","article-title":"DrugCentral 2023 extends human clinical data and integrates veterinary drugs","volume":"51","author":"Avram","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.arr.2024.102651_bib10","doi-asserted-by":"crossref","first-page":"8959","DOI":"10.1038\/s41598-018-27395-0","article-title":"Repositioning of omarigliptin as a once-weekly intranasal anti-parkinsonian agent","volume":"8","author":"Ayoub","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2024.102651_bib11","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1126\/science.abj8754","article-title":"Accurate prediction of protein structures and interactions using a three-track neural network","volume":"373","author":"Baek","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.arr.2024.102651_bib12","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.7861\/fhj.2021-0095","article-title":"Artificial intelligence in healthcare: transforming the practice of medicine","volume":"8","author":"Bajwa","year":"2021","journal-title":"Future Healthc. J."},{"key":"10.1016\/j.arr.2024.102651_bib13","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3390\/pharmaceutics15020693","article-title":"Therapeutic potential of dopamine and related drugs as anti-inflammatories and antioxidants in neuronal and non-neuronal pathologies","volume":"15","author":"Bandala","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.arr.2024.102651_bib14","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/ejn.14079","article-title":"Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced dyskinesia","volume":"49","author":"Bariotto-dos-Santos","year":"2019","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.arr.2024.102651_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113413","article-title":"Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia","volume":"333","author":"Bartlett","year":"2020","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.arr.2024.102651_bib16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1742-1241.1986.tb07976.x","article-title":"Treatment of Parkinson's disease with orphenadrine alone and in combination with L-dopa","volume":"40","author":"Bassi","year":"1986","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.arr.2024.102651_bib17","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.drudis.2020.11.037","article-title":"Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 2: a discussion of chemical and biological data","volume":"26","author":"Bender","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.arr.2024.102651_bib18","article-title":"SB-0107, a drug repurposing opportunity identified through machine learning, shows the potential to treat Parkinson\u2019s disease motor disability and levodopa-induced dyskinesia in rat and primate models","volume":"36","author":"Bordbar","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2024.102651_bib19","article-title":"FP0011 eXtends the Duration of the Anti-parkinsonian Actions of L-dopa and Reduces L-dopa-Induced Dyskinesia in the MPTP-Lesioned Macaque Model of Parkinson's Disease","volume":"111","author":"Brotchie","year":"2007"},{"key":"10.1016\/j.arr.2024.102651_bib20","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1021\/ci0341161","article-title":"Comparison of support vector machine and artificial neural network systems for drug\/nondrug classification","volume":"43","author":"Byvatov","year":"2003","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"10.1016\/j.arr.2024.102651_bib21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.arr.2024.102651_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.gpb.2017.07.003","article-title":"Deep learning and its applications in biomedicine","volume":"16","author":"Cao","year":"2018","journal-title":"Genom.\u00a0Proteom. Bioinf."},{"key":"10.1016\/j.arr.2024.102651_bib23","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/minf.201400009","article-title":"Computational prediction of drug\u25ab target interactions using chemical, biological, and network features","volume":"33","author":"Cao","year":"2014","journal-title":"Mol. Inf."},{"key":"10.1016\/j.arr.2024.102651_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fnagi.2020.00031","article-title":"Neuroprotection by the immunomodulatory drug pomalidomide in the Drosophila LRRK2WD40 genetic model of Parkinson\u2019s disease","volume":"12","author":"Casu","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.arr.2024.102651_bib25","series-title":"Machine Learning: A Practitioner's Approach","author":"Chandra","year":"2021"},{"key":"10.1016\/j.arr.2024.102651_bib26","first-page":"229","article-title":"A novel fuzzy credit risk assessment decision support system based on the python web framework","volume":"37","author":"Chang","year":"2020","journal-title":"J. Ind. Prod. Eng."},{"key":"10.1016\/j.arr.2024.102651_bib27","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.drudis.2018.01.039","article-title":"The rise of deep learning in drug discovery","volume":"23","author":"Chen","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.arr.2024.102651_bib28","first-page":"14","article-title":"Introduction to machine learning, neural networks, and deep learning","volume":"9","author":"Choi","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.arr.2024.102651_bib29","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/mds.27077","article-title":"Ceftriaxone reduces l-dopa\u2013induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model","volume":"32","author":"Chotibut","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2024.102651_bib30","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1021\/acs.chemrestox.8b00393","article-title":"Advancing computational toxicology in the big data era by artificial intelligence: data-driven and mechanism-driven modeling for chemical toxicity","volume":"32","author":"Ciallella","year":"2019","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.arr.2024.102651_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1404338","article-title":"Artificial intelligence in drug repurposing for rare diseases: a mini-review","volume":"11","author":"Cortial","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.arr.2024.102651_bib32","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s10462-021-10058-4","article-title":"Machine learning in drug discovery: a review","volume":"55","author":"Dara","year":"2022","journal-title":"Artif. Intell. Rev."},{"key":"10.1016\/j.arr.2024.102651_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40537-019-0217-0","article-title":"Big data in healthcare: management, analysis and future prospects","volume":"6","author":"Dash","year":"2019","journal-title":"J. Big Data"},{"key":"10.1016\/j.arr.2024.102651_bib34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1108\/LR-06-2015-0061","article-title":"A formal definition of big data based on its essential features","volume":"65","author":"De Mauro","year":"2016","journal-title":"Libr. Rev."},{"key":"10.1016\/j.arr.2024.102651_bib35","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","article-title":"Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model","volume":"179","author":"Dekundy","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.arr.2024.102651_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40263-012-0017-y","article-title":"Methylphenidate: a treatment for Parkinson\u2019s disease?","volume":"27","author":"Devos","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.arr.2024.102651_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105256","article-title":"Doxycycline inhibits \u03b1-synuclein-associated pathologies in vitro and in vivo","volume":"151","author":"Dominguez-Meijide","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2024.102651_bib38","article-title":"Levetiracetam ameliorates L-DOPA-Induced dyskinesia in hemiparkinsonian rats inducing critical molecular changes in the striatum","volume":"2015","author":"Du","year":"2015","journal-title":"Parkinson's Dis."},{"key":"10.1016\/j.arr.2024.102651_bib39","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/bib\/bbr013","article-title":"Exploiting drug\u2013disease relationships for computational drug repositioning","volume":"12","author":"Dudley","year":"2011","journal-title":"Brief. Bioinf."},{"key":"10.1016\/j.arr.2024.102651_bib40","article-title":"The potential applications of artificial intelligence in drug discovery and development","volume":"70","author":"Farghali","year":"2021","journal-title":"Physiol. Res."},{"key":"10.1016\/j.arr.2024.102651_bib41","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.3390\/s20154220","article-title":"Deep learning sensor fusion for autonomous vehicle perception and localization: a review","volume":"20","author":"Fayyad","year":"2020","journal-title":"Sensors"},{"key":"10.1016\/j.arr.2024.102651_bib42","doi-asserted-by":"crossref","first-page":"8336","DOI":"10.1038\/s41598-019-44803-1","article-title":"Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats","volume":"9","author":"Fletcher","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2024.102651_bib43","first-page":"155","article-title":"The fourth industrial revolution is the AI revolution an academy prospective","volume":"8","author":"Fouad","year":"2019","journal-title":"Int. J. Inf."},{"key":"10.1016\/j.arr.2024.102651_bib44","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2024.102651_bib45","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00344251","article-title":"Neocognitron: a self-organizing neural network model for a mechanism of pattern recognition unaffected by shift in position","volume":"36","author":"Fukushima","year":"1980","journal-title":"Biol. Cybern."},{"key":"10.1016\/j.arr.2024.102651_bib46","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.nbd.2015.11.022","article-title":"Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: behavioral, molecular, and synaptic mechanisms","volume":"86","author":"Ghiglieri","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2024.102651_bib47","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.biopha.2018.11.127","article-title":"An update on Drug Repurposing: re-written saga of the drug\u2019s fate","volume":"110","author":"Gns","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.arr.2024.102651_bib48","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/archneur.1983.04050120035003","article-title":"Pergolide in Parkinson's disease","volume":"40","author":"Goetz","year":"1983","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.arr.2024.102651_bib49","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/mds.20828","article-title":"Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease","volume":"21","author":"Gomez-Ramirez","year":"2006","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.arr.2024.102651_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-76927-0","article-title":"CMT-3 targets different \u03b1-synuclein aggregates mitigating their toxic and inflammogenic effects","volume":"10","author":"Gonz\u00e1lez-Liz\u00e1rraga","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2024.102651_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep41755","article-title":"Repurposing doxycycline for synucleinopathies: remodelling of \u03b1-synuclein oligomers towards non-toxic parallel beta-sheet structured species","volume":"7","author":"Gonz\u00e1lez-Liz\u00e1rraga","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2024.102651_bib52","series-title":"Applied Machine Learning","author":"Gopal","year":"2019"},{"key":"10.1016\/j.arr.2024.102651_bib53","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/1389202922666210705124359","article-title":"Machine Learning in Healthcare","volume":"22","author":"Habehh","year":"2021","journal-title":"Curr. Genom."},{"key":"10.1016\/j.arr.2024.102651_bib54","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.tips.2019.05.005","article-title":"Artificial intelligence for clinical trial design","volume":"40","author":"Harrer","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.arr.2024.102651_bib55","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3389\/fonc.2017.00273","article-title":"Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics","volume":"7","author":"Hernandez","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.arr.2024.102651_bib56","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1162\/neco.2006.18.7.1527","article-title":"A fast learning algorithm for deep belief nets","volume":"18","author":"Hinton","year":"2006","journal-title":"Neural Comput."},{"key":"10.1016\/j.arr.2024.102651_bib57","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1126\/science.1127647","article-title":"Reducing the dimensionality of data with neural networks","volume":"313","author":"Hinton","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.arr.2024.102651_bib58","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1477-7525-11-167","article-title":"Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective","volume":"11","author":"Hirji","year":"2013","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.arr.2024.102651_bib59","series-title":"2016 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)","first-page":"6082","article-title":"Automatic Assessment of Medication States of Patients with Parkinson's Disease Using Wearable Sensors","author":"Hssayeni","year":"2016"},{"key":"10.1016\/j.arr.2024.102651_bib60","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.medengphy.2019.03.002","article-title":"Assessment of response to medication in individuals with Parkinson\u2019s disease","volume":"67","author":"Hssayeni","year":"2019","journal-title":"Med. Eng. Phys."},{"key":"10.1016\/j.arr.2024.102651_bib61","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.045815","article-title":"Machine learning discriminates a movement disorder in a zebrafish model of Parkinson's disease","volume":"13","author":"Hughes","year":"2020","journal-title":"Dis. Models Mech."},{"key":"10.1016\/j.arr.2024.102651_bib62","first-page":"97","article-title":"Pharmaceutical and pharmacokinetic evaluation of a newly formulated multiparticulate matrix of levodopa and carbidopa","volume":"11","author":"Imbeah","year":"2023","journal-title":"Admet dmpk"},{"key":"10.1016\/j.arr.2024.102651_bib63","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/mds.24994","article-title":"Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy","volume":"27","author":"Ishigami","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2024.102651_bib64","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneurol.2017.140","article-title":"Exenatide\u2013a drug for diabetes and Parkinson disease?","volume":"13","author":"Jankovic","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2024.102651_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13321-020-00450-7","article-title":"A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions","volume":"12","author":"Jarada","year":"2020","journal-title":"J. Chemin.-."},{"key":"10.1016\/j.arr.2024.102651_bib66","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0006-8993(99)01657-1","article-title":"Narrow beneficial effect of dextromethorphan on levodopa-induced motor response alterations in an experimental model of parkinsonism","volume":"839","author":"Jim\u00e9nez","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.arr.2024.102651_bib67","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.drudis.2013.11.005","article-title":"Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines","volume":"19","author":"Jin","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.arr.2024.102651_bib68","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/mds.27565","article-title":"Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques","volume":"34","author":"Johnston","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2024.102651_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.109880","article-title":"Using artificial intelligence to identify drugs for repurposing to treat l-DOPA-induced dyskinesia","volume":"248","author":"Johnston","year":"2024","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2024.102651_bib70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuropharm.2018.05.035","article-title":"Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease","volume":"147","author":"Johnston","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2024.102651_bib71","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s12951-024-02882-x","article-title":"Personalized mRNA vaccines in glioblastoma therapy: from rational design to clinical trials","volume":"22","author":"Karimi-Sani","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.arr.2024.102651_bib72","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s11030-021-10274-8","article-title":"Recent trends in artificial intelligence-driven identification and development of anti-neurodegenerative therapeutic agents","volume":"25","author":"Kashyap","year":"2021","journal-title":"Mol. Divers."},{"key":"10.1016\/j.arr.2024.102651_bib73","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.neuropharm.2017.08.015","article-title":"Metformin lowers \u03b1-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson's disease","volume":"125","author":"Katila","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2024.102651_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116442","article-title":"Artificial intelligence-driven drug repositioning uncovers efavirenz as a modulator of \u03b1-synuclein propagation: implications in Parkinson\u2019s disease","volume":"174","author":"Kim","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.arr.2024.102651_bib75","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.parkreldis.2014.01.016","article-title":"Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease","volume":"20","author":"Kobylecki","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.arr.2024.102651_bib76","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.3390\/ijms23031851","article-title":"A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics","volume":"23","author":"Lamptey","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2024.102651_bib77","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.patrec.2014.01.008","article-title":"A review of unsupervised feature learning and deep learning for time-series modeling","volume":"42","author":"L\u00e4ngkvist","year":"2014","journal-title":"Pattern Recognit. Lett."},{"key":"10.1016\/j.arr.2024.102651_bib78","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/ars.2015.6549","article-title":"Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's disease","volume":"25","author":"Lastres-Becker","year":"2016","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.arr.2024.102651_bib79","article-title":"Drug repurposing is a new opportunity for developing drugs against neuropsychiatric disorders","volume":"2016","author":"Lee","year":"2016","journal-title":"Schizophr. Res. Treat."},{"key":"10.1016\/j.arr.2024.102651_bib80","doi-asserted-by":"crossref","first-page":"3","DOI":"10.23876\/j.krcp.2017.36.1.3","article-title":"Medical big data: promise and challenges","volume":"36","author":"Lee","year":"2017","journal-title":"Kidney Res. Clin. Pract."},{"key":"10.1016\/j.arr.2024.102651_bib81","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nbd.2015.01.003","article-title":"Enhanced histamine H2 excitation of striatal cholinergic interneurons in L-DOPA-induced dyskinesia","volume":"76","author":"Lim","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2024.102651_bib82","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2174\/1568026033452096","article-title":"The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery","volume":"3","author":"Lin","year":"2003","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.arr.2024.102651_bib83","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.3390\/molecules27154780","article-title":"Identification of potential parkinson & rsquo;s disease drugs based on multi-source data fusion and convolutional neural network","volume":"27","author":"Liu","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.arr.2024.102651_bib84","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3390\/v12091058","article-title":"Drug repositioning: new approaches and future prospects for life-debilitating diseases and the COVID-19 pandemic outbreak","volume":"12","author":"Low","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.arr.2024.102651_bib85","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.arr.2024.102651_bib86","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41467-017-00680-8","article-title":"A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information","volume":"8","author":"Luo","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.arr.2024.102651_bib87","doi-asserted-by":"crossref","DOI":"10.1002\/pds.5015","article-title":"Identifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology","volume":"29","author":"Maclagan","year":"2020","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.arr.2024.102651_bib88","doi-asserted-by":"crossref","first-page":"11052","DOI":"10.1039\/C9CC04251B","article-title":"An aminoglycoside antibiotic inhibits both lipid-induced and solution-phase fibrillation of \u03b1-synuclein in vitro","volume":"55","author":"Mahapatra","year":"2019","journal-title":"Chem. Commun."},{"key":"10.1016\/j.arr.2024.102651_bib89","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.drudis.2018.11.014","article-title":"Artificial intelligence in drug development: present status and future prospects","volume":"24","author":"Mak","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.arr.2024.102651_bib90","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/agm2.12243","article-title":"Neurodegenerative disorders: assessing the impact of natural vs drug-induced treatment options","volume":"6","author":"Mathur","year":"2023","journal-title":"Aging Med. (Milton (N. S. W))"},{"key":"10.1016\/j.arr.2024.102651_bib91","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/mds.21656","article-title":"Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial","volume":"22","author":"Mendon\u00e7a","year":"2007","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.arr.2024.102651_bib92","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.2174\/1381612811319380011","article-title":"Erythropoietin: a neuroprotective agent in cerebral hypoxia, neurodegeneration, and epilepsy","volume":"19","author":"Merelli","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.arr.2024.102651_bib93","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/23808993.2017.1380516","article-title":"The role of artificial intelligence in precision medicine","volume":"2","author":"Mesko","year":"2017","journal-title":"Expert Rev. Precis. Med. Drug Dev."},{"key":"10.1016\/j.arr.2024.102651_bib94","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1126\/science.aaf3934","article-title":"\u03b22-Adrenoreceptor is a regulator of the \u03b1-synuclein gene driving risk of Parkinson\u2019s disease","volume":"357","author":"Mittal","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.arr.2024.102651_bib95","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.trci.2017.10.005","article-title":"Drug discovery and development: role of basic biological research","volume":"3","author":"Mohs","year":"2017","journal-title":"Alzheimer's\u00a0Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.arr.2024.102651_bib96","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.trci.2017.10.005","article-title":"Drug discovery and development: role of basic biological research","volume":"3","author":"Mohs","year":"2017","journal-title":"Alzheimer'S. Dement. (N. Y., N. Y. )"},{"key":"10.1016\/j.arr.2024.102651_bib97","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.parkreldis.2020.05.011","article-title":"Machine learning-assisted neurotoxicity prediction in human midbrain organoids","volume":"75","author":"Monzel","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.arr.2024.102651_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24129933","article-title":"Neurobiology of Parkinson's disease","volume":"24","author":"Morelli","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2024.102651_bib99","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.healthpol.2010.12.002","article-title":"The cost of drug development: a systematic review","volume":"100","author":"Morgan","year":"2011","journal-title":"Health Policy"},{"key":"10.1016\/j.arr.2024.102651_bib100","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nrd2961","article-title":"Lessons from 60 years of pharmaceutical innovation","volume":"8","author":"Munos","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.arr.2024.102651_bib101","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0168-0102(01)00298-X","article-title":"Zonisamide has beneficial effects on Parkinson's disease patients","volume":"41","author":"Murata","year":"2001","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.arr.2024.102651_bib102","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s13205-022-03165-8","article-title":"Deep learning tools for advancing drug discovery and development","volume":"12","author":"Nag","year":"2022","journal-title":"3 Biotech"},{"key":"10.1016\/j.arr.2024.102651_bib103","article-title":"Machine learning: applications of artificial intelligence to imaging and diagnosis","volume":"11","author":"Nichols","year":"2018","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.arr.2024.102651_bib104","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.tips.2013.03.004","article-title":"Challenges and opportunities of drug repositioning","volume":"34","author":"Novac","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.arr.2024.102651_bib105","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1006\/exnr.2002.8009","article-title":"Quetiapine attenuates Levodopa-induced motor complications in rodent and primate Parkinsonian models","volume":"177","author":"Oh","year":"2002","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.arr.2024.102651_bib106","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/17453674.2021.1918389","article-title":"Presenting artificial intelligence, deep learning, and machine learning studies to clinicians and healthcare stakeholders: an introductory reference with a guideline and a Clinical AI Research (CAIR) checklist proposal","volume":"92","author":"Olczak","year":"2021","journal-title":"Acta Orthop."},{"key":"10.1016\/j.arr.2024.102651_bib107","first-page":"157","article-title":"Drug repositioning: concept, classification, methodology, and importance in rare\/orphans and neglected diseases","volume":"8","author":"de Oliveira","year":"2018","journal-title":"J. Appl. Pharm. Sci."},{"key":"10.1016\/j.arr.2024.102651_bib108","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ddstr.2011.10.002","article-title":"Drug repurposing from an academic perspective","volume":"8","author":"Oprea","year":"2011","journal-title":"Drug Discov. Today. Ther. Strateg."},{"key":"10.1016\/j.arr.2024.102651_bib109","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4252\/wjsc.v15.i7.687","article-title":"Neural stem cells for Parkinson's disease management: challenges, nanobased support, and prospects","volume":"15","author":"Oz","year":"2023","journal-title":"World J. Stem Cells"},{"key":"10.1016\/j.arr.2024.102651_bib110","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s43440-020-00095-1","article-title":"Metformin protects rotenone-induced dopaminergic neurodegeneration by reducing lipid peroxidation","volume":"72","author":"Ozbey","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.arr.2024.102651_bib111","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JPD-160867","article-title":"Nilotinib effects in Parkinson\u2019s disease and dementia with Lewy bodies","volume":"6","author":"Pagan","year":"2016","journal-title":"J. Parkinson's Dis."},{"key":"10.1016\/j.arr.2024.102651_bib112","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JPD-160867","article-title":"Nilotinib effects in Parkinson's disease and dementia with Lewy bodies","volume":"6","author":"Pagan","year":"2016","journal-title":"J. Parkinson's Dis."},{"key":"10.1016\/j.arr.2024.102651_bib113","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.tips.2019.06.003","article-title":"Insights into computational drug repurposing for neurodegenerative disease","volume":"40","author":"Paranjpe","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.arr.2024.102651_bib114","series-title":"Deep Learning: A Practitioner's Approach","author":"Patterson","year":"2017"},{"key":"10.1016\/j.arr.2024.102651_bib115","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drudis.2020.10.010","article-title":"Artificial intelligence in drug discovery and development","volume":"26","author":"Paul","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.arr.2024.102651_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.nsa.2024.104061","article-title":"Research progress of cell treatment strategy in Parkinson's disease","volume":"3","author":"Peng","year":"2024","journal-title":"Neurosci. Appl."},{"key":"10.1016\/j.arr.2024.102651_bib117","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1093\/bioinformatics\/bty133","article-title":"A novel computational approach for drug repurposing using systems biology","volume":"34","author":"Peyvandipour","year":"2018","journal-title":"Bioinformatics"},{"key":"10.1016\/j.arr.2024.102651_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112275","article-title":"A medicinal chemistry perspective of drug repositioning: recent advances and challenges in drug discovery","volume":"195","author":"Pillaiyar","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.arr.2024.102651_bib119","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neurobiolaging.2016.08.004","article-title":"Neuroprotective and immunomodulatory effects of raloxifene in the myenteric plexus of a mouse model of Parkinson's disease","volume":"48","author":"Poirier","year":"2016","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2024.102651_bib120","doi-asserted-by":"crossref","unstructured":"Potashkin, J.A., Santiago, J.A., Ravina, B.M., Watts, A., Leontovich, A.A., 2012. Biosignatures for Parkinson\u2019s Disease and Atypical Parkinsonian Disorders Patients.","DOI":"10.1371\/journal.pone.0043595"},{"key":"10.1016\/j.arr.2024.102651_bib121","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/ana.24375","article-title":"Dual \u03ba-agonist\/\u03bc-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of P arkinson disease","volume":"77","author":"Potts","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.arr.2024.102651_bib122","article-title":"Current therapies in clinical trials of Parkinson's disease: a 2021 update","volume":"14","author":"Prasad","year":"2021"},{"key":"10.1016\/j.arr.2024.102651_bib123","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.arr.2024.102651_bib124","article-title":"Exploring the paradox of COVID-19 in neurological complications with emphasis on Parkinson\u2019s and Alzheimer\u2019s disease","volume":"2022","author":"Rai","year":"2022","journal-title":"Oxid. Med. Cell\u00a0Longev."},{"key":"10.1016\/j.arr.2024.102651_bib125","doi-asserted-by":"crossref","first-page":"8505","DOI":"10.1111\/jcmm.14674","article-title":"Levetiracetam treatment ameliorates LRRK2 pathological mutant phenotype","volume":"23","author":"Rassu","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.arr.2024.102651_bib126","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2018.12.007","article-title":"inPentasomes: an innovative nose-to-brain pentamidine delivery blunts MPTP parkinsonism in mice","volume":"294","author":"Rinaldi","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.arr.2024.102651_bib127","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s13311-018-0646-z","article-title":"Angiotensin type 1 receptor antagonists protect against alpha-synuclein-induced neuroinflammation and dopaminergic neuron death","volume":"15","author":"Rodriguez-Perez","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.arr.2024.102651_bib128","first-page":"24","article-title":"Orphenadrine in the treatment of Parkinson's disease","volume":"5","author":"RR","year":"1964","journal-title":"Curr. Med. Drugs"},{"key":"10.1016\/j.arr.2024.102651_bib129","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.nbd.2010.05.001","article-title":"A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys","volume":"39","author":"Rylander","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2024.102651_bib130","first-page":"71","article-title":"Artificial intelligence and deep learning: the future of medicine and medical practice","volume":"67","author":"Sanal","year":"2019","journal-title":"J. Assoc. Physicians India"},{"key":"10.1016\/j.arr.2024.102651_bib131","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.arr.2024.102651_bib132","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s42979-021-00815-1","article-title":"Deep learning: a comprehensive overview on techniques, taxonomy, applications and research directions","volume":"2","author":"Sarker","year":"2021","journal-title":"SN Comput. Sci."},{"key":"10.1016\/j.arr.2024.102651_bib133","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41422-019-0153-8","article-title":"Vitamin B12 modulates Parkinson\u2019s disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection","volume":"29","author":"Schaffner","year":"2019","journal-title":"Cell Res."},{"key":"10.1016\/j.arr.2024.102651_bib134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-016-0838-4","article-title":"Changing R&D models in research-based pharmaceutical companies","volume":"14","author":"Schuhmacher","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.arr.2024.102651_bib135","article-title":"QSAR modelling to identify LRRK2 inhibitors for parkinson\u2019s disease","volume":"16","author":"Sebasti\u00e1n-P\u00e9rez","year":"2019","journal-title":"J. Integr. Bioinf."},{"key":"10.1016\/j.arr.2024.102651_bib136","first-page":"1","article-title":"Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries","author":"Selvaraj","year":"2021","journal-title":"Mol. Divers."},{"key":"10.1016\/j.arr.2024.102651_bib137","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188212","article-title":"Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment","volume":"13","author":"Shao","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.arr.2024.102651_bib138","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1038\/s41467-019-09494-2","article-title":"Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing","volume":"10","author":"Siddiqi","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.arr.2024.102651_bib139","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12874-019-0681-4","article-title":"Machine learning in medicine: a practical introduction","volume":"19","author":"Sidey-Gibbons","year":"2019","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.arr.2024.102651_bib140","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/mds.20345","article-title":"Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease","volume":"20","author":"Silverdale","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2024.102651_bib141","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jamaneurol.2020.4725","article-title":"Efficacy of Nilotinib in patients with moderately advanced parkinson disease: a randomized clinical trial","volume":"78","author":"Simuni","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2024.102651_bib142","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.neuropharm.2006.08.018","article-title":"Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates","volume":"52","author":"Smith","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2024.102651_bib143","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/10715762.2017.1353688","article-title":"Potential repositioning of exemestane as a neuroprotective agent for Parkinson\u2019s disease","volume":"51","author":"Son","year":"2017","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.arr.2024.102651_bib144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2018.04.005","article-title":"Pluripotent stem cell-based therapy for Parkinson\u2019s disease: current status and future prospects","volume":"168","author":"Sonntag","year":"2018","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.arr.2024.102651_bib145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10916-019-1419-x","article-title":"Decision-making based on big data analytics for people management in healthcare organizations","volume":"43","author":"Sousa","year":"2019","journal-title":"J. Med. Syst."},{"key":"10.1016\/j.arr.2024.102651_bib146","article-title":"QSAR modelling to identify LRRK2 inhibitors for Parkinson\u2019s disease","volume":"16","author":"Sp","year":"2019","journal-title":"J. Integr. Bioinf."},{"key":"10.1016\/j.arr.2024.102651_bib147","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.parkreldis.2005.03.005","article-title":"High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias","volume":"11","author":"Storch","year":"2005","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.arr.2024.102651_bib148","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1089\/adt.2017.776","article-title":"Validating the predicted effect of astemizole and ketoconazole using a Drosophila model of Parkinson's disease","volume":"15","author":"Styczy\u0144ska-Soczka","year":"2017","journal-title":"Assay. Drug Dev. Technol."},{"key":"10.1016\/j.arr.2024.102651_bib149","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.drudis.2016.10.008","article-title":"Drug repurposing by integrated literature mining and drug\u2013gene\u2013disease triangulation","volume":"22","author":"Sun","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.arr.2024.102651_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108771","article-title":"Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease","volume":"198","author":"Tohge","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2024.102651_bib151","doi-asserted-by":"crossref","DOI":"10.1093\/jncimonographs\/lgx011","article-title":"Integrating traditional and allopathic medicine: an opportunity to improve global health in cancer","volume":"2017","author":"Trimble","year":"2017","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"10.1016\/j.arr.2024.102651_bib152","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuroscience.2014.01.042","article-title":"Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease","volume":"265","author":"Tronci","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.arr.2024.102651_bib153","first-page":"581","article-title":"Sustainable industrial and operation engineering trends and challenges Toward Industry 4.0: a data driven analysis","volume":"38","author":"Tseng","year":"2021","journal-title":"J. Ind. Prod. Eng."},{"key":"10.1016\/j.arr.2024.102651_bib154","first-page":"3974","article-title":"In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson\u2019s disease","volume":"27","author":"Uenaka","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.arr.2024.102651_bib155","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41573-019-0024-5","article-title":"Applications of machine learning in drug discovery and development","volume":"18","author":"Vamathevan","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.arr.2024.102651_bib156","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(04)15945-X","article-title":"Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease","volume":"363","author":"Van Camp","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2024.102651_bib157","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.3390\/molecules24122220","article-title":"Serum N-glycosylation in Parkinson\u2019s disease: a novel approach for potential alterations","volume":"24","author":"V\u00e1radi","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.arr.2024.102651_bib158","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/med.21764","article-title":"Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: state-of-the-arts and future directions","volume":"41","author":"Vatansever","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.arr.2024.102651_bib159","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/life14020233","article-title":"Integrating artificial intelligence for drug discovery in the context of revolutionizing drug delivery","volume":"14","author":"Visan","year":"2024","journal-title":"Life"},{"key":"10.1016\/j.arr.2024.102651_bib160","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2174\/1570193X13666160728121823","article-title":"An approach for drug discovery","volume":"13","author":"Vora","year":"2016","journal-title":"Mini-rev. Org. Chem."},{"key":"10.1016\/j.arr.2024.102651_bib161","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/bioinformatics\/bty543","article-title":"NeoDTI: neural integration of neighbor information from a heterogeneous network for discovering new drug\u2013target interactions","volume":"35","author":"Wan","year":"2019","journal-title":"Bioinformatics"},{"key":"10.1016\/j.arr.2024.102651_bib162","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s12967-023-04484-x","article-title":"Cell-therapy for Parkinson's disease: a systematic review and meta-analysis","volume":"21","author":"Wang","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.arr.2024.102651_bib163","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/jnr.23439","article-title":"L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum","volume":"92","author":"Wang","year":"2014","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.arr.2024.102651_bib164","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-019-02871-3","article-title":"An AI boost for clinical trials","volume":"573","author":"Woo","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.arr.2024.102651_bib165","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7150\/ijbs.24612","article-title":"Review of drug repositioning approaches and resources","volume":"14","author":"Xue","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.arr.2024.102651_bib166","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12539-021-00487-8","article-title":"Machine learning applications in drug repurposing","volume":"14","author":"Yang","year":"2022","journal-title":"Interdiscip. Sci.\u00a0Comput. Life Sci."},{"key":"10.1016\/j.arr.2024.102651_bib167","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1042\/ETLS20210223","article-title":"Artificial intelligence unifies knowledge and actions in drug repositioning","volume":"5","author":"Yin","year":"2021","journal-title":"Emerg. Top. Life Sci."},{"key":"10.1016\/j.arr.2024.102651_bib168","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1109\/MSP.2010.939038","article-title":"Deep learning and its applications to signal and information processing [exploratory dsp].","volume":"28","author":"Yu","year":"2010","journal-title":"IEEE Signal Process. Mag."},{"key":"10.1016\/j.arr.2024.102651_bib169","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/abr.abr_170_23","article-title":"The application of artificial intelligence and drug repositioning for the identification of fibroblast growth factor receptor inhibitors: a review","volume":"13","author":"Zarei","year":"2024","journal-title":"Adv. Biomed. Res."},{"key":"10.1016\/j.arr.2024.102651_bib170","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1093\/bioinformatics\/btz418","article-title":"deepDR: a network-based deep learning approach to in silico drug repositioning","volume":"35","author":"Zeng","year":"2019","journal-title":"Bioinformation"},{"issue":"7","key":"10.1016\/j.arr.2024.102651_bib171","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1039\/C9SC04336E","article-title":"Target identification among known drugs by deep learning from heterogeneous networks","volume":"11","author":"Zeng","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.arr.2024.102651_bib172","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/fi13010014","article-title":"Drug repurposing for Parkinson\u2019s disease by integrating knowledge graph completion model and knowledge fusion of medical literature","volume":"13","author":"Zhang","year":"2021","journal-title":"Future Internet"},{"key":"10.1016\/j.arr.2024.102651_bib173","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/fi13010014","article-title":"Drug repurposing for Parkinson\u2019s disease by integrating knowledge graph completion model and knowledge fusion of medical literature","volume":"13","author":"Zhang","year":"2021","journal-title":"Future Internet"},{"key":"10.1016\/j.arr.2024.102651_bib174","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/mds.26453","article-title":"\u03b17 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage","volume":"30","author":"Zhang","year":"2015","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.arr.2024.102651_bib175","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JPD-181503","article-title":"Semaglutide is neuroprotective and reduces \u03b1-synuclein levels in the chronic MPTP mouse model of Parkinson\u2019s disease","volume":"9","author":"Zhang","year":"2019","journal-title":"J. Parkinson's Dis."},{"key":"10.1016\/j.arr.2024.102651_bib176","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/stcltm\/szac006","article-title":"Neural stem\/progenitor cell transplantation in Parkinson\u2019s rodent animals: a meta-analysis and systematic review","volume":"11","author":"Zheng","year":"2022","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.arr.2024.102651_bib177","doi-asserted-by":"crossref","DOI":"10.1108\/LHT-08-2019-0170","article-title":"Drug repurposing against Parkinson's disease by text mining the scientific literature","author":"Zhu","year":"2020","journal-title":"Libr. Hi Tech. Ahead--Print."},{"key":"10.1016\/j.arr.2024.102651_bib178","first-page":"48","article-title":"TGF-beta1 mediates hypoxia-preconditioned olfactory mucosa mesenchymal stem cells improved neural functional recovery in Parkinson's disease models and patients","volume":"11","author":"Zhuo","year":"2024","journal-title":"Mil. Med. Res."}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163724004690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163724004690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T16:59:13Z","timestamp":1738861153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163724004690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":178,"alternative-id":["S1568163724004690"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2024.102651","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug repositioning for Parkinson\u2019s disease: An emphasis on artificial intelligence approaches","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2024.102651","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102651"}}